A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

NCT00257608 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1145

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: bevacizumab
DRUG: placebo
DRUG: erlotinib HCl

Sponsor

Genentech, Inc.